Valneva SE

VALN Nasdaq CIK: 0001836564

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Accelerated filer
State of Incorporation France
Business Address 6, RUE ALAIN BOMBARD, SAINT-HERBLAIN, I0, 44800
Mailing Address 6, RUE ALAIN BOMBARD, SAINT-HERBLAIN, I0, 44800
Phone 33 2 28 07 37 10
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
6-K Foreign company current report March 26, 2026 View on SEC
6-K Foreign company current report March 23, 2026 View on SEC
6-K Foreign company current report March 18, 2026 View on SEC
20-F Foreign company annual report March 17, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 10, 2026 View on SEC
6-K Foreign company current report March 9, 2026 View on SEC
6-K Foreign company current report March 2, 2026 View on SEC
6-K Foreign company current report February 19, 2026 View on SEC
6-K Foreign company current report February 13, 2026 View on SEC
6-K Foreign company current report February 3, 2026 View on SEC

Annual Reports

20-F March 17, 2026
  • U.S. FDA approval of IXCHIQ, the world's first Chikungunya vaccine, opening doors for commercialization in the U.S. and other territories.
  • Lyme disease vaccine (VLA15) remains a cornerstone, undergoing Phase 3 clinical trials with Pfizer, with data readouts expected in the near future.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.